1. Home
  2. HDL vs COLL Comparison

HDL vs COLL Comparison

Compare HDL & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

HDL

SUPER HI INTERNATIONAL HOLDING LTD. American Depositary Shares

N/A

Current Price

$14.98

Market Cap

941.4M

ML Signal

N/A

Logo Collegium Pharmaceutical Inc.

COLL

Collegium Pharmaceutical Inc.

HOLD

Current Price

$31.96

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HDL
COLL
Founded
2016
2002
Country
Singapore
United States
Employees
13651
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
941.4M
1.2B
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
HDL
COLL
Price
$14.98
$31.96
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$51.17
AVG Volume (30 Days)
848.0
538.0K
Earning Date
05-20-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
1.73
Revenue
N/A
$780,567,000.00
Revenue This Year
$10.47
$5.93
Revenue Next Year
$14.04
N/A
P/E Ratio
$55.56
$18.73
Revenue Growth
N/A
23.62
52 Week Low
$14.51
$23.23
52 Week High
$23.62
$50.79

Technical Indicators

Market Signals
Indicator
HDL
COLL
Relative Strength Index (RSI) 38.25 23.00
Support Level N/A $31.01
Resistance Level $17.71 $32.92
Average True Range (ATR) 0.21 1.31
MACD -0.12 -0.06
Stochastic Oscillator 23.66 0.29

Price Performance

Historical Comparison
HDL
COLL

About HDL SUPER HI INTERNATIONAL HOLDING LTD. American Depositary Shares

Super Hi International Holding Ltd is an investment holding company and its subsidiaries are principally engaged in restaurant operations, delivery business, and sales of hot pot condiment products and food ingredients located in the overseas market outside Mainland China, Hong Kong, Macau, and Taiwan. Its mission is to become a world-wide integrated restaurant group, build the world's Chinese cuisine brand, and promote Chinese culinary heritage world-wide.

About COLL Collegium Pharmaceutical Inc.

Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.

Share on Social Networks: